Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Imv Inc. (IMV.TO)

Imv Inc. (IMV.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 302,592
  • Shares Outstanding, K 67,094
  • Annual Sales, $ 59 K
  • Annual Income, $ -27,365 K
  • 60-Month Beta 2.08
  • Price/Sales 7,038.09
  • Price/Cash Flow N/A
  • Price/Book 6.20
Trade IMV.TO with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.61
  • Most Recent Earnings -0.13 on 09/30/20
  • Next Earnings Date 03/29/21
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.15
  • Number of Estimates 2
  • High Estimate -0.15
  • Low Estimate -0.15
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +11.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.31 +3.02%
on 02/24/21
5.86 -24.23%
on 02/05/21
-0.25 (-5.33%)
since 01/22/21
3-Month
3.61 +22.99%
on 12/23/20
5.86 -24.23%
on 02/05/21
-0.02 (-0.45%)
since 11/24/20
52-Week
1.98 +124.24%
on 03/23/20
9.25 -52.00%
on 07/14/20
-1.91 (-30.08%)
since 02/24/20

Most Recent Stories

More News
Marburg Hemorrhagic Fever Drug Market Segmented Application and Geography Trends, Growth and Forecasts to 2020 - 2027 By Ameco Research

pune, India, Mon, 22 Feb 2021 05:34:05 / Comserve Inc. / -- Marburg Hemorrhagic Fever Drug market is segmented by Type, and by Application. Players, stakeholders, and other

GSK : 34.60 (+0.64%)
IMV.TO : 4.44 (-1.55%)
SRPT : 83.43 (-0.47%)
Covid-19 Impact: Baculoviral IAP Repeat Containing Protein 5 Market To Grow At A Much Faster Rate Beyond 2020| Financial Analysis And Forecast

Baculoviral IAP Repeat Containing Protein 5 Businesses must navigate the financial and operational challenges of coronavirus while rapidly addressing the needs of their people, customers, and suppliers....

IMV.TO : 4.44 (-1.55%)
IMV to Participate in Two Upcoming Investor Events

IMV Inc. ("IMV" or the "Corporation") (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today...

IMV.TO : 4.44 (-1.55%)
IMV : 3.57 (+0.85%)
Zika Virus Vaccines Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027

The research report titled Zika Virus Vaccines offers comprehensive information on key driving factors, pricing analysis, market growth trends, brand positioning, competitive landscape, product usage and...

CERS : 6.82 (+0.74%)
GSK : 34.60 (+0.64%)
IMV.TO : 4.44 (-1.55%)
INO : 12.01 (+2.83%)
XON : 4.65 (-4.12%)
NLNK : 0.8900 (-12.75%)
TKPYY : 16.5900 (-0.90%)
IMV Reports Update on COVID-19 Vaccine Program

--Vaccine candidate is stable at 2�C to 8�C and room temperature for at least 3 months and ongoing

IMV.TO : 4.44 (-1.55%)
IMV : 3.57 (+0.85%)
BTV Shines a Light on Companies to Invest In

Vancouver, British Columbia--(Newsfile Corp. - December 10, 2020) - On national TV Sat. Dec 12 & Sun. Dec 13, 2020 - spotlights the newest mining, cannabis, tech and pharmaceutical companies for investment...

IMV.TO : 4.44 (-1.55%)
VEXT.CN : 1.200 (+3.45%)
TCAN.CN : 1.500 (+2.74%)
CMMC.TO : 3.46 (+6.13%)
ROXG.TO : 1.44 (-0.69%)
ROGFF : 1.1464 (-0.31%)
CVV.VN : 0.550 (+14.58%)
CVVUF : 0.4394 (+13.34%)
GSQ.CN : 0.490 (unch)
TMX Group, IMV, C-Suite at The Open

TMX Group, IMV, C-Suite at The Open

IMV.TO : 4.44 (-1.55%)
X.TO : 122.57 (-1.03%)
Durable Clinical Benefits Induced by IMV's T Cell Therapy in Combination With Merck's Keytruda in Subjects With PD-L1 Positive r/r DLBCL Presented at ASH Annual Meeting

--PD-L1 positive subjects demonstrated Objective Response Rate (ORR) of 86 % associated with long duration of clinical benefits

MRK : 75.07 (+0.71%)
IMV.TO : 4.44 (-1.55%)
IMV : 3.57 (+0.85%)
IMV's Survivin-Targeted T Cell Therapy Shows Durable Clinical Benefits in Phase 2 Study in Patients with Hard-to-Treat Advanced Recurrent Ovarian Cancer

--12-month overall survival rate of 66.1%

IMV.TO : 4.44 (-1.55%)
IMV : 3.57 (+0.85%)
IMV to Host a Key Opinion Leader Webcast on the Ovarian Cancer Treatment Landscape and Data Highlights from the Phase 2 Trial of a Novel T-Cell Therapy

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that the Company...

IMV.TO : 4.44 (-1.55%)
IMV : 3.57 (+0.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Key Turning Points

3rd Resistance Point 5.09
2nd Resistance Point 4.92
1st Resistance Point 4.71
Last Price 4.44
1st Support Level 4.33
2nd Support Level 4.16
3rd Support Level 3.95

See More

52-Week High 9.25
Fibonacci 61.8% 6.47
Fibonacci 50% 5.61
Fibonacci 38.2% 4.76
Last Price 4.44
52-Week Low 1.98

See More

Business Summary

IMV Inc is a clinical-stage biopharmaceutical company. The company is engaged in making immunotherapies more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. Its proprietary drug development platform provides a patented delivery formulation...

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar